|Company:||Paskewitz, Barry J.|
|Subject:||Illegal Drug Residue|
|Issuer:||Minneapolis District Office|
|Issued:||Feb. 26, 2008||Closed:||
Department of Health and Human Services
Public Health Service
Minneapolis District Office
RETURN RECEIPT REQUESTED
February 26, 2008
Refer to MIN 08-09
Barry J. Paskewitz
116 Baker Drive
Redwood Falls, Minnesota 56283
Dear Mr. Paskewitz:
An investigation of your cattle operation located in Redwood Falls, Minnesota, was conducted by investigators from the Minnesota Department of Agriculture, acting on behalf of the U.S. Food and Drug Administration ( FDA), on December 13, 2007. This investigation confirmed that you offered an animal for sale for slaughter as food that was adulterated under sections 402(a)(2)(C)(ii) and 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. §§ 342(a)(2)(C)(ii) and 342(a)(4)]. You can find the Act and its associated regulations on the Internet through links on the FDA web page at www.fda.gov .
On or about July 9, 2007, you consigned [redacted] a livestock hauler to transport a lot of 36 cows (cows were not identified individually) to [redacted] for slaughter as food. On or about July 10 2007, this lot of 36 cows was assigned lot identification [redacted] and slaughtered at [redacted] . United States Department of Agriculture, Food Safety and Inspection Service (USDA/FSIS) analyses of tissue samples collected from a cow identified with house tag [redacted] from lot [redacted] identified the presence of 0.21 parts per million (ppm) penicillin in kidney tissue.
A tolerance of 0.05 ppm has been established for residues of penicillin in the uncooked edible tissues of cattle as codified in Title 21, Code of Federal Regulations , section 556.510 (21 CFR § 556.510). The presence of this drug in excess of this amount in uncooked edible tissues from this animal causes the food to be adulterated within the meaning of section 402(a)(2)(C)(ii) of the Act 121 U.S.C.§.342(a)(2)(C)(ii)].
Our investigation found that you hold animals under conditions that are so inadequate that medicated animals bearing potentially harmful drug residues may enter the food supply. Food from animals held under such conditions, is adulterated within the meaning of section 402(a)(4)] of the Act [21.U.S.C. § 342(a)(4)]. You lack a system to ensure that animals you buy, feed, and then sell for slaughter as food have not been medicated or, if they have been medicated, to allow you to withhold the animals from slaughter for an appropriate period of time to deplete potentially hazardous residues of drugs from edible tissues.
You should take prompt action to correct the above violations and to establish procedures whereby such violations do not recur. Failure to do so may result in regulatory action without further notice such as seizure and/or injunction.
The above is not intended to be an all-inclusive list of violations. It is your responsibility to ensure that your operations are in compliance with the law. As a buyer, feeder, and seller of animals intended for slaughter as food, you are frequently the individual who introduces or offers for introduction into interstate commerce the adulterated animal. As such, you share the responsibility for violating the Federal Food, Drug, and Cosmetic Act. To avoid future illegal residue violations, you should take precautions such as implementing a system or systems to determine and record the source of the animal, to determine whether the animal has been medicated and with what drug(s), and to withhold the animal from slaughter for an appropriate period of time to deplete potentially hazardous residues of drugs from edible tissue.
You should notify this office in writing within 15 working days of the steps you have taken to bring your firm into compliance with the law. Your response should include each step being taken, that has been taken, or will be taken to correct the violations and to prevent their recurrence. If corrective action cannot be completed within 15 working days, state the reason for the delay and the time frame within which the corrections will be completed. Please include copies of any available documentation demonstrating that corrections have been made.
Your written response should be sent to Dr. Brian D. Garthwaite, Compliance Officer, at the address located on the letterhead. If you have any questions about this letter, please contact Dr. Garthwaite at (612) 758-7132.
(for)W. Charles Becoat